(Q34997106)

5 August 2017

1 reference

title

Does chemotherapy have a role as palliative therapy for unfit or elderly patients with non-small-cell lung cancer? (English)

1 reference

5 August 2017

1 reference

1

Cesare Gridelli

1 reference

5 August 2017

publication date

1 November 2002

1 reference

5 August 2017

1 reference

5 August 2017

volume

38 Suppl 2

1 reference

5 August 2017

page(s)

S45-50

1 reference

Global cancer statistics in the year 2000.

5 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900357-4

7 January 2021

Lung cancer in the elderly

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900357-4

7 January 2021

The National Institute on Aging and the National Cancer Institute SEER collaborative study on comorbidity and early diagnosis of cancer in the elderly

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900357-4

7 January 2021

Age and the treatment of lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900357-4

7 January 2021

Prevalence of co-morbidity in lung cancer patients and its relationship with treatment: a population-based study.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900357-4

7 January 2021

Measuring comorbidity in older cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900357-4

7 January 2021

Perspectives on comorbidity and cancer in older patients: approaches to expand the knowledge base

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900357-4

7 January 2021

Hemopoietic reserve in the older cancer patient: clinical and economic considerations

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900357-4

7 January 2021

Geriatric oncology: challenges for the new century

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900357-4

7 January 2021

Chemotherapy in the elderly: pharmacologic considerations

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900357-4

7 January 2021

Non-small cell lung cancer in very young and very old patients

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900357-4

7 January 2021

Underrepresentation of patients 65 years of age or older in cancer-treatment trials

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900357-4

7 January 2021

Effects of Vinorelbine on Quality of Life and Survival of Elderly Patients With Advanced Non-Small-Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900357-4

7 January 2021

Randomized trial of paclitaxel plus supportive care versus supportive care for patients with advanced non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900357-4

7 January 2021

A multicenter, randomized, phase III study of docetaxel plus best supportive care versus best supportive care in chemotherapy-naive patients with metastatic or non-resectable localized non-small cell lung cancer (NSCLC).

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900357-4

7 January 2021

Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer--a randomized trial with quality of life as the primary outcome. UK NSCLC Gemcitabine Group. Non-Small Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900357-4

7 January 2021

Gemcitabine plus vinorelbine in nonsmall cell lung carcinoma patients age 70 years or older or patients who cannot receive cisplatin. Oncopaz Cooperative Group

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900357-4

7 January 2021

Gemcitabine plus vinorelbine in elderly or unfit patients with non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900357-4

7 January 2021

Effectiveness of chemotherapy for advanced lung cancer in the elderly: instrumental variable and propensity analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900357-4

7 January 2021

Chemotherapy of advanced non small cell lung cancer in the elderly: an update

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900357-4

7 January 2021

Management of elderly patients with lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900357-4

7 January 2021

Weekly vinorelbine in elderly patients with non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900357-4

7 January 2021

Vinorelbine chemotherapy in non small cell lung cancer: experience in elderly patients

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900357-4

7 January 2021

Vinorelbine is well tolerated and active in the treatment of elderly patients with advanced non-small cell lung cancer. A two-stage phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900357-4

7 January 2021

Vinorelbine treatment of advanced non-small cell lung cancer with special emphasis on elderly patients

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900357-4

7 January 2021

Vinorelbine in elderly patients with inoperable nonsmall cell lung carcinoma: a phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900357-4

7 January 2021

Gemcitabine monotherapy in elderly patients with advanced non-small cell lung cancer: a multicenter phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900357-4

7 January 2021

Activity and toxicity of gemcitabine and gemcitabine + vinorelbine in advanced non-small-cell lung cancer elderly patients: Phase II data from the Multicenter Italian Lung Cancer in the Elderly Study (MILES) randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900357-4

7 January 2021

Retrospective comparison of toxicity and efficacy in phase II trials of 3-h infusions of paclitaxel for patients 70 years of age or older and patients under 70 years of age

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900357-4

7 January 2021

Weekly docetaxel in the treatment of elderly patients with advanced nonsmall cell lung carcinoma. A Minnie Pearl Cancer Research Network Phase II Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900357-4

7 January 2021

Prospective evaluation of the feasibility of cisplatin-based chemotherapy for elderly lung cancer patients with normal organ functions

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900357-4

7 January 2021

Analysis of thrombocytopenia due to carboplatin combined with etoposide in elderly patients with lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900357-4

7 January 2021

Gemcitabine plus vinorelbine versus vinorelbine alone in elderly patients with advanced non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900357-4

7 January 2021

10.1016/S0169-5002(02)00357-4

Identifiers

DOI

1 reference

5 August 2017

1 reference